Sygnature Discovery’s Group Invests in New Start Up, Peak Proteins
News Jan 28, 2016
Sygnature Discovery, the UK’s largest independent provider of drug discovery expertise has invested, through it’s parent Sygil Group, in a new start-up company.
The deal, which was signed in December, sees Sygil making a significant investment in the BioHub-based business at Alderley Park, Cheshire, UK. This partnership adds protein production and crystallography to Sygnature’s current range of discovery services.
Peak Proteins was founded by Dr Mark Abbott in 2014 and has been trading since last summer. Collectively, the highly experienced team provides engineered, bespoke protein reagents and 3D atomic level structures of proteins using X-ray crystallography to enable the rational design of new drugs.
Commenting, Sygnature Discovery Founder, Dr Simon Hirst said, “Computational structure-based design is a very important part of modern drug discovery and Peak Proteins’ team of highly experienced scientists offer a rare skill set in protein production which compliments and supports our existing capabilities. This is much more than a financial investment as we will be able to share our management expertise with Peak Proteins and support their future growth.”
He continued, “Our involvement means that we can now offer protein production and crystallography alongside our client projects, or separately, and this expands our capabilities further. The two companies will also be able to work together to develop new services and technologies that will be advantageous to our clients.”
Dr Mark Abbott, Founder of Peak Proteins, said, “It is great to have the expertise and involvement of Simon and his team at Sygnature Discovery. There is a lot we can learn from their successes as we grow our business. Working together in this way will give us the necessary cash injection to accelerate our growth as well as making some important capital investments in equipment.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE